Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8996706 | 0.98 | IDO1 (0.52) | ALDH1A1FFAR4IDO1KEAP1GLA | |
| Hydrochloric Acid SCHEMBL4372850 | 0.98 | IDO1 (0.52) | ALDH1A1FFAR4IDO1KEAP1GLA | |
| SCHEMBL24244880 | 0.82 | ALDH1A1 (0.48) | ALDH1A1FFAR4IDO1KEAP1GLA | |
| SCHEMBL186087 | 0.81 | KIF11 (0.48) | ALDH1A1FFAR4IDO1KEAP1GLA | |
| SCHEMBL29978561 | 0.81 | KIF11 (0.48) | ALDH1A1FFAR4IDO1KEAP1GLA | |
| SCHEMBL279009 | 0.79 | ALDH1A1 (0.50) | ALDH1A1FFAR4IDO1KEAP1GAA | |
| SCHEMBL21332700 | 0.78 | SCN9A (0.47) | ALDH1A1FFAR4IDO1GAASMN1; SMN2 | |
| SCHEMBL29972896 | 0.78 | FFAR4 (0.61) | ALDH1A1FFAR4IDO1FFAR1 | |
| SCHEMBL29403371 | 0.78 | KIF11 (0.50) | ALDH1A1FFAR4GLAPOLBGAA | |
| SCHEMBL349356 | 0.78 | KIF11 (0.50) | ALDH1A1FFAR4GLAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119592176-A | Quick-drying corrosion-resistant finish paint and preparation process thereof | 江苏安特克新材料研究院有限公司 | 2025-03-11 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1377579-B1 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMA INC (US) | 2009-03-25 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1524261-B1 | Process for preparing fluorinated anilines | SALTIGO GMBH (DE) | 2008-06-11 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7154006-B2 | Preparation of fluorinated anilines | BAYER AKTIENGESELLSCHAFT (DE) | 2006-12-26 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050101795-A1 | Preparation of fluorinated anilines | BAYER CHEMICALS AG | 2005-05-12 | — | — | US | claimed |
| EP-1524261-A1 | Process for preparing fluorinated anilines | Bayer Chemicals AG (DE) | 2005-04-20 | — | — | EP | claimed |
| US-6861524-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-01 | — | — | US | claimed |
| EP-1377579-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Aventis Pharmaceuticals Inc. (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTISUB LLC | 2003-04-10 | — | — | US | claimed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-5354495-A | Homo- or copolymerizable through ethylenic unsaturation | NIPPON PAINT CO., LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| EP-0177122-B1 | ACRYLAMIDE DERIVATIVES | Nippon Paint Co., Ltd. (JP) | 1992-04-01 | — | — | EP | claimed |
| US-4935413-A | ELASTICITY, ADHESION AND DISPERSIBILITY | NIPPON PAINT CO., LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-0174131-A2 | Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
| US-4145364-A | PREPARATION OF FLUORINATED ANILINES | MERCK & CO., INC. (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101795-A1 | Preparation of fluorinated anilines | FLNA, FLNB, FLI1 | ALDH1A1 559/4885FFAR4 591/4885IDO1 721/4885 |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | BAD, BAX, MCL1 | ALDH1A1 1022/4885FFAR4 437/4885IDO1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.